Eledon Pharmaceuticals Inc. has announced that updated clinical data from its ongoing Phase 1b trial of tegoprubart, an anti-CD40L antibody, will be presented at the upcoming World Transplant Congress 2025 in San Francisco. The open-label study focuses on the prevention of rejection in patients undergoing kidney transplantation. The oral presentation, scheduled for August 6, 2025, will feature results from approximately 30 kidney transplant recipients and will be delivered by Dr. John Gill from the University of British Columbia. The presentation will be part of the session on "Kidney Novel Immunosuppressant Strategies." Additionally, Eledon will sponsor a satellite symposium at the congress and present new preclinical data on tegoprubart in a poster session. A copy of the oral presentation will be available on the company's website following the session.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。